Description
MK0683, also known as Vorinostat or SAHA (Suberoylanilide Hydroxamic Acid), is an investigational medication that has been studied in patients with relapsed or refractory colorectal cancer. Relapsed means the cancer came back after initial treatment, and refractory means it didn't respond to initial treatment. This drug was studied in Phase 2 clinical trials, often in combination with other treatments. The goal of these trials was to see how well MK0683 worked in shrinking tumors or slowing their growth in patients whose cancer had returned or wasn't responding to standard therapies. Researchers also wanted to evaluate the safety and side effects of the drug. The specific trial mentioned (NCT00126451) also studied MK0683 in breast and lung cancers and looked at using PET scans to monitor response.
Mechanism of Action
MK0683 (Vorinostat) belongs to a class of drugs called histone deacetylase inhibitors (HDAC inhibitors). HDACs are enzymes that play a role in regulating gene expression. By inhibiting these enzymes, MK0683 can affect the behavior of cancer cells, potentially leading to their death or slowing their growth. The specific way it impacts colorectal cancer cells is still being studied, but it is thought to interfere with the processes that allow cancer cells to survive and multiply.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.